ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: NCI Figure Left unchanged By Carter; Pay Raise Puts further Squeeze On Institute Budget

March 4, 1977

Letters: Kopans To Broder: Response Ignores Major Questions

October 15, 1993

Frei, Freireich Share One GM Prize; Ames, Erikson Win Others

June 17, 1983

Tobacco Interests Contribute a Portion Of the $109 Million Raised by Stand Up To Cancer

September 12, 2014

Senate Committee Adds $100 Million for Cancer, Earmarks Extra Positions for NCI, Backs New Construction

September 19, 1975

Survival For ALL Increased To 94 Percent In Recent Years

December 31, 2010